Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis

References

• ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994;343:271-75
   PubMed Web of Science ®Google Scholar
• National MS Society Information Sourcebook: Epidemiology. National Multiple Sclerosis Society Web site. http://main.nationalmssociety.org/docs/HOM/epidemiology.pdf. Accessed December 19, 2008
   Google Scholar
• Avonex (interferon beta-1a) [package insert]. Cambridge, MA: Biogen Idec, Inc., 2006
   Google Scholar
• Betaseron (interferon beta-1b) [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals Inc., 2007
   Google Scholar
• Rebif (interferon beta-1a) [package insert]. Rockland, MA: EMD Serono, Inc., 2008
   Google Scholar
• Copaxone (glatiramer acetate) [package insert]. Kansas City, MO: Teva Neuroscience, Inc., 2007
   Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
   PubMed Web of Science ®Google Scholar
• Tysabri (natalizumab) [package insert]. Cambridge, MA: Biogen Idec, Inc., 2008
   Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation for progressive multifocal leukoencephalopathy in natalizumab treated patients. N Engl J Med 2006;354:924-33
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Modeling the cost effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler 2008;14:679-90
   PubMed Web of Science ®Google Scholar
• Gani R, Giovannoni G, Bates D, et al. Cost effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-27
   PubMed Web of Science ®Google Scholar
• Multiple sclerosis – natalizumab: natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. National Institute for Health and Clinical Excellence (NICE) Web site. http://www.nice.org.uk/Guidance/TA127. Issued August 2007. Accessed December 19, 2008
   Google Scholar
• Multiple sclerosis – beta interferon and glatiramer acetate. National Institute for Health and Clinical Excellence (NICE) Web site. http://www.nice.org.uk/Guidance/TA32. Issued January 2002. Accessed December 19, 2008
   Google Scholar
• Joyce AT, Iacoviello JM, Nag S, et al. End-stage renal disease–associated managed care costs among patients with and without diabetes. Diabetes Care 2004;27:2829-35
   PubMed Web of Science ®Google Scholar
• Campbell DE, Lynn J, Louis TA, et al. Medicare program expenditures associated with hospice use. Ann Intern Med 2004;140:269-77
   PubMed Web of Science ®Google Scholar
• Ozminkowski RJ, Marder WD, Hawkins K, et al. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. Clin Ther 2004;26:1341-54
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Siva A, Ward J, et al. Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted County, Minnesota. Neurology 2004;44:28-33
   Google Scholar
• 2008 Physicians’ Fee and Coding Guide. MAG Mutual Healthcare Solutions, Inc., Duluth, GA
   Google Scholar
• Tice AD, Hoaglund PA, Nolet B, et al. Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy 2002;22:63-70S
   PubMed Web of Science ®Google Scholar
• Beckerman H, van Zee IE, de Groot V, et al. Utilization of health care by patients with multiple sclerosis is based on professional and patient-defined health needs. Mult Scler 2008;14:1269-79
   PubMed Web of Science ®Google Scholar
• Rudick R, Sandrock AW. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurotherapeutics 2004;4:571-80
   PubMedGoogle Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17-28
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics. Consumer Price Index: December 2002. Washington, DC: US Bureau of Labor Statistics; January 16, 2003. Publication USDL-03-15
   Google Scholar
• US Bureau of Labor Statistics. Consumer Price Index: October 2006. Washington, DC: US Bureau of Labor Statistics; November 16, 2006. Publication USDL-06-1979
   Google Scholar
• Fox EJ, Vartanian TK, Zamvil SS. The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist 2007;13:355-62
   PubMed Web of Science ®Google Scholar
• Treadaway K, Brannon K, Morrison A, et al. Factors that influence adherence with disease-modifying therapy in multiple sclerosis. Poster presented at: 58th Annual Meeting of the American Academy of Neurology; April 1-8, 2006; San Diego, CA
   Google Scholar
• O’Rourke KET, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50
   PubMed Web of Science ®Google Scholar
• Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-β treatment for multiple sclerosis. Neurol Sci 2003;24:361-4
   PubMed Web of Science ®Google Scholar
• Thompson JP, Noyes K, Dorsey ER, et al. Quantitative risk-benefit analysis of natalizumab. Neurology 2008;71:357-64
   PubMed Web of Science ®Google Scholar